There were 96 generic drugs approved and 30 generic drugs tentatively approved. This sharp increase in approvals for generics follows five months of declining generic approvals.
More competition from generics is thought to be a critical component of lowering drug prices.
In July, the FDA also sent an annual high of 357 complete response letters, which are sent to companies to communicate that the agency has completed its review of a new or generic drug application and it will not approve the generic in its present form.
More articles on pharmacy:
Teva’s revenue drops 18% in Q2
Express Scripts to drop coverage of 48 drugs next year
Trump to make drug price announcement next week
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.